1.5.3.13	1,12-diaminododecane	1,12-diaminododecane derivatives could represent good candidates for the development of novel highly specific mPAO inhibitors	5228	
1.5.3.13	1,8-diaminooctane	competitive versus the polyamine	2927	
1.5.3.13	6,6'-[ethane-1,2-diyldi(piperidine-4,1-diyl)]bis[N-[(2-methoxyphenyl)methyl]hexan-1-amine]	17fold selectivity for spermine oxidase over polyamine oxidase	261605	
1.5.3.13	Chlorhexidine	-	20680	
1.5.3.13	guazatine	-	3712	
1.5.3.13	MDL72527	-	9981	
1.5.3.13	MDL72527	irreversible. In addition to the covalent adduct, a second MDL72527 molecule is bound in the active site. Binding of MDL72527 is accompanied by altered conformations in the APAO backbone	9981	
1.5.3.13	methoctramine	120fold selectivity for spermine oxidase over polyamine oxidase	261891	
1.5.3.13	additional information	no inhibition at pH 7.5: 1,8-diaminooctane. Comparative study on murine PAO (mPAO) and SMO (mSMO) inhibition. The different behaviour displayed by 1,12-diaminododecane towards mPAO and mSMO reveals the occurrence of basic differences in the ligand binding mode of the two enzymes, the first enzyme interacting mainly with substrate secondary amino groups and the second one with substrate primary amino groups. The data provide the basis for the development of novel and selective inhibitors able to discriminate between mammalian SMO and PAO activities	2	
1.5.3.13	additional information	no inhibitory activity: N-(3-aminopropyl)-N-2-propynyl-1,4-butanediamine and N-[3-(2-propynylamino)propyl]-1,4-butanediamine	2	
1.5.3.13	N,N-di-2,3-butadienyl-1,4-butanediamine	i.e. MDL 72527, strong inhibition	220821	
1.5.3.13	N,N'-butanedienyl butanediamine	i.e. MDL 72527 or CPC-200, a small molecule specific inhibitor of polyamine oxidase, effectively blocks androgen-induced reactive oxygen species production in human prostate cancer cells, as well as significantly delays prostate cancer progression and death in animals developing spontaneous prostate cancer	155225	
1.5.3.13	N-(3-aminopropyl)-N-2-propenyl-1,4-butanediamine	moderate inhibition	220822	
1.5.3.13	N-(3-aminopropyl)-N-2,3-butadienyl-1,4-butanediamine	strong inhibition	220819	
1.5.3.13	N-prenylagmatine	-	7694	
1.5.3.13	N-[3-(2,3-butadienylamino)propyl]-1,4-butanediamine	strong inhibition	220820	
1.5.3.13	N-[3-(2-propenylamino) propyl]-1,4-butanediamine	moderate inhibition	220823	
1.5.3.13	N1,N1'-(pentane-1,5-diyl)bis[N6-[(2-methoxyphenyl)methyl]hexane-1,6-diamine]	9fold selectivity for spermine oxidase over polyamine oxidase	262089	
1.5.3.13	N1,N4-bis(2,3-butadienyl)-1,4-butanediamine	i.e. MDL 72,527	9783	
1.5.3.13	N1,N4-bis(2,3-butadienyl)-1,4-butanediamine	2.5 mM, 70% inhibition of N1-acetylspermine oxidation	9783	
1.5.3.13	N1,N7-bis(6-[[(2-methoxyphenyl)methyl]amino]hexyl)heptane-1,7-diamine	40fold selectivity for spermine oxidase over polyamine oxidase	262092	
1.5.3.13	N1-acetyl-1,12-diaminododecane	competitive versus the polyamine	155228	
1.5.3.13	N1-acetyl-1,8-diaminooctane	competitive versus the polyamine	155226	
1.5.3.13	N1-acetyl-N3-pentyl-1,3-diaminopropane	competitive versus the polyamine	155227	
1.5.3.13	N8-acetylspermine	-	21869	
1.5.3.13	putrescine	-	155	
1.5.3.13	SL-11144	0.01 mM, 80% inhibition	55921	
1.5.3.13	SL-11150	0.01 mM, complete inhibition	55923	
1.5.3.13	SL-11158	0.01 mM, complete inhibition	55922	
1.5.3.13	spermidine	-	148	
1.5.3.13	spermine	-	197